Noncomparative phase 2 RCT in pretreated advanced neuroendocrine carcinoma (169 of 185 analysed): objective response at 8 weeks was 7.2% with nivolumab and 14.0% with nivolumab-ipilimumab; median PFS about 2 months and OS about 6 months in both arms.
RCTn = 185 patients
Walter et al. Nivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trial